Biosensors International Announces Positive Follow-up Data from First Patient in European STEALTH I Drug-Eluting Stent Trial 

•  Follow-up procedure transmitted live from Germany to JIM cardiology conference in Rome 

February, 2004 - A follow-up procedure on a 67-year-old female with a history of hypertension, hyperlipidemia, a previous AMI (acute myocardial infarction, or heart attack) and a family history of cardiac artery disease was performed by Eberhard Grube , MD and colleagues at Heart Center Siegburg in Germany . The procedure was transmitted live on February 12, 2004 to this year's annual Joint Interventional Meeting (JIM) in Rome, Italy.

A follow-up intravascular ultrasound study (IVUS) and angiogram showed that at six months following implantation, the patient remained free of any sign of restenosis, despite the tortuous configuration of the patient's left anterior descending artery (LAD) at the site of the implant, and despite the tendency of earlier-generation stents to cause restenosis.

Dr. Grube's original stent implantation procedure on this patient, on September 15, 2003, was also transmitted live from Heart Center Siegburg to the annual Transcatheter Cardiovascular Therapeutics (TCT) conference in Washington, DC . A clinical trial of MATRIXT, code-named the STEALTH I trial, has been underway in Europe since then.